All In Biotech

Drug Trial Radar · NCT03478488

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 472 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

472

Actual

Start

Apr 16, 2018

Primary completion

Sep 10, 2024

Study completion Sep 10, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer. The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.

Conditions

  • Biliary Tract Neoplasms

Interventions

  • KN035 plus Gemcitabine & oxaliplatinDrug

    KN035 a programmed death ligand immune check inhibitor Per Investigator decision

  • Gemcitabine & oxaliplatinDrug

    The standard of care for the patients with unresectable/metastatic biliary tract cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Observed by 12 weeks after progressive disease or end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Chinese people's liberation army (PLA) 81hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.